Needham & Company Starts Neothetics Inc. (NEOT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Piper Jaffray Starts Neothetics Inc. (NEOT) at Overweight
December 15, 2014 6:39 AM ESTPiper Jaffray initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Overweight rating and a price target of $20.00.
Analyst David Amsellem comments, "NEOT, in our view, is well positioned to expand and transform the emerging body contouring space with LIPO-202, an injectable form... More
Guggenheim Starts Neothetics Inc. (NEOT) at Buy
December 15, 2014 6:04 AM ESTGuggenheim initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Buy rating and a price target of $16.00.
Analyst Louise Chen highlighted the company's two products in development:
LIPO-202 (Salmeterol Xinafoate for Injection): Injectable designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty).LIPO-102 (Salmeterol Xinafoate and Fluticasone Propionate): Orphan designation for treatment of... More